Patents by Inventor Christoph Van Amsterdam

Christoph Van Amsterdam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidine alcohols
    Patent number: 6756370
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2 and A have the meanings given in claim 1, are potent 5-HT2A antagonists and are suitable for treating psychoses, schizophrenia, depression, neurological disorders, impaired memory, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia and anorexia nervosa, Pre-Menstrual Syndrome and/or for positively influencing obsessive-compulsive disorders, (OCD).
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: June 29, 2004
    Assignee: Merck Patent GmbH
    Inventors: Helmut Prücher, Henning Böttcher, Karl-August Ackermann, Rudolf Gottschlich, Christoph van Amsterdam, Christoph Seyfried, Jürgen Harting, Gerd Bartoszyk, Hartmut Greiner
  • Piperazinylcarbonylquinolines and -isoquinolines
    Publication number: 20040077657
    Abstract: Compound of the formula (I) in which R1, R2 and alk are as defined in Claim 1, are potent 5-HT2A antagonist and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Hutington's disease, eating disorders, such as bulimia, anorexia nervosa, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).
    Type: Application
    Filed: July 17, 2003
    Publication date: April 22, 2004
    Inventors: Henning Bottcher, Gerd Bartoszyk, Jurgen Harting, Christoph van Amsterdam, Christoph Seyfried
  • Indole derivatives
    Patent number: 6723725
    Abstract: Indole derivatives of formula I, their salts and solvates, have valuable pharmacological properties together with good tolerability, as they have actions on the central nervous system: wherein R1 and R3 are as defined herein. The compounds have a strong affinity for 5-HT2A receptors, and furthermore exhibit 5HT2A receptor-antagonistic properties. These are therefore suitable both in veterinary and in human medicine for the treatment of functional disorders of the central nervous system and also of inflammation.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: April 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Henning Böttcher, Joachim März, Hartmut Greiner, Jürgen Harting, Gerd Bartoszyk, Christoph Seyfried, Christoph van Amsterdam
  • Arylpiperazine derivatives and their use as psychotropic agents
    Publication number: 20040014972
    Abstract: The invention relates to arylpiperazine derivatives of formula (I), wherein R1, R2, A, B, Ar and n have the given meanings.
    Type: Application
    Filed: March 5, 2003
    Publication date: January 22, 2004
    Inventors: Rudolf Gottschlich, Dieter Dorsch, Gerd Bartosyk, Jurgen Harting, Christoph Seyfried, Christoph van Amsterdam
  • Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1receptors and/or dopamine d2 receptors
    Publication number: 20040014768
    Abstract: Novel chromenone derivatives of the formula I 1
    Type: Application
    Filed: February 21, 2003
    Publication date: January 22, 2004
    Inventors: Rudolf Gottschlich, Karl-Augst Ackermann, Helmut Prcher, Christoph Seyfried, Gerd Bartoszyk, Christoph Van Amsterdam
  • Amide and urea derivatives as 5-HT reuptake inhibitors and as5-HT1B/1D ligands
    Publication number: 20030064995
    Abstract: Amide and urea derivatives of the formula I
    Type: Application
    Filed: September 10, 2002
    Publication date: April 3, 2003
    Applicant: MERCK PATENT GMBH
    Inventors: Christoph Van Amsterdam, Hartmut Greiner, Henning Boettcher, Gerd Bartoszyk, Juergen Harting, Lisa Matzen, Wilfried Rautenberg
  • Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands
    Patent number: 6509340
    Abstract: Amide and urea derivatives of the formula I R1—(CH2)n—(Y)q—(Z)r—CO—NH—R2  (I) in which R1, n, Y, q, Z, r and R2 have the meanings indicated in Claim 1, are potent 5-HT1B/1D antagonists and exhibit 5-HT reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depressions, schizophrenia, compulsive ideas, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive behaviour (OCD), and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: January 21, 2003
    Assignee: Merck Patentgesellschaft
    Inventors: Christoph Van Amsterdam, Hartmut Greiner, Henning Boettcher, Gerd Bartoszyk, Juergen Harting, Lisa Matzen, Wilfried Rautenberg